FDA/NIH dental MOU
This article was originally published in The Gray Sheet
Memorandum of understanding between FDA and the National Institutes of Health's National Institute of Dental Research has as its "principal goal" the reduction of time between the research and development phase of a dental product's life cycle and its commercial availability, FDA says in a June 2 Federal Register notice. The MOU will "facilitate interactions between" NIDR and the agency regarding "improvements in the quality and relevance of pre-clinical and clinical research" on products for use in oral health care. By enhancing the quality of product-related research, the organizations will "facilitate and improve premarket evaluations"...
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19.
FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.